^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Small Cell Squamous Cancer
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/16/2021
    Excerpt:
    Squamous cell carcinoma…Other recommended…Nivolumab/ipilimumab/paclitaxel/carboplatin
    Secondary therapy:
    carboplatin + paclitaxel
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    02/16/2021
    Excerpt:
    Squamous cell carcinoma…Other recommended…Nivolumab/ipilimumab
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    JAMA Oncol
    Title:

    Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer

    Published date:
    07/15/2021
    Excerpt:
    NON-SUPPORTIVE EVIDENCE: Median survival was 10 months (95% CI, 8.0-14.4 months) in the nivolumab/ipilimumab group and 11 months (95% CI, 8.6-13.7 months) in the nivolumab group....In this phase 3 randomized clinical trial, ipilimumab added to nivolumab did not improve outcomes in patients with advanced, pretreated, immune checkpoint inhibitor–naive SqNSCLC.
    DOI:
    10.1001/jamaoncol.2021.2209
    Trial ID:
    Lung-Map Sub-Study